Johnson & Johnson's Stelara Crohn's Disease and Ulcerative Colitis Trials Successfully

CompilationTom Lee

A few days ago, Johnson & Johnson published interleukin (IL)-12 and IL-23 inhibitor Stelara (ustekinumab) as Crohn’s disease ( Positive trial results of first-line treatments for CD) and ulcerative colitis (UC)

The trial results show that compared with second-line or third-line treatment, Stelara as a first-line treatment is associated with longer clinical remission or longer clinical response time in adult patients with moderate to severe active ulcerative colitis, including delaying the time for patients to undergo surgery

Christopher Gasink, MD, head of Gastroenterology and Immunomedical Affairs at Janssen Scientific, said that the data generated by these analyses provide doctors with additional evidence to support Stelara as a moderately to severely active Crohn’s disease and ulcerative colitis.

The results of clinical trials for ulcerative colitis show that Stelara is more effective as a first-line therapy than as a second-line or third-line therapy

Another study in a clinical trial for Crohn’s disease showed that compared with patients who started using adalimumab, patients who started using Stelara had a higher proportion of continued treatment, including patients who continued to receive treatment and did not use corticosteroids.

According to the latest data, Johnson & Johnson Stelara's actual revenue in the third quarter was US$2.

Reference source: New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis